Tigermed
Tigermed is a contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.
Tigermed, founded in December, 2014 and headquartered in Hangzhou, is a contract research organization (CRO) focused on providing professional services for the entire process of clinical trials for new drug research. The founder is Ye Xiaoping. Listed on the SZSE on August 17, 2012, the company's major shareholders are Ye Xiaoping, Hong Kong Securities Clearing Co., Ltd and Cao Xiaochun. Rivals that have direct and indirect competition with Tigermed include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Cro plate fell, and Wuxi apptec fell nearly 10%
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Technology, Real Estate, IndustrialsTech for Global, Globalization Footprints of the Established and the New
Research
Technology, Real Estate, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Baidu responded that it was unable to search "referee document network": caused by misoperation of the technical team
NK Celltech Receives a Series A Round of Funding Worth More Than CNY 100 Million
NK Celltech recently received a Series A round of funding totaling more than CNY 100 million. Huagai Capital led this round of funding, which was followed by CASVC, Unifortune, 呈益资本, Sirius Capital, and QJ Capital.
Jul 01, 2022 03:58 PM
WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell
According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index. It has been considered a top holding by many MSCI China indexes for some time.
Jun 08, 2020 09:51 AM
Cro stocks rose in early trading